Central precocious puberty in children with Lennox–Gastaut syndrome: clinical characteristics and long-term outcomes of GnRH agonist treatment

In the complex landscape of human development, the body follows a strict internal clock that dictates when a child transitions into adulthood. For most, this process begins in the early teenage years, but for some, the signal arrives far too soon. This condition, known as central precocious puberty, occurs when the brain's command center for reproduction activates prematurely, causing secondary sexual characteristics to appear before the age of eight in girls or nine in boys. Without intervention, this early start accelerates bone maturation, causing children to grow quickly at first but then stop growing sooner than expected, often resulting in a shorter adult height. The standard treatment involves a medication that acts like a temporary pause button, silencing the hormonal signal to allow the child's growth to continue for a longer period. While doctors have long understood how to treat this condition in healthy children, a significant gap remained in knowledge regarding children with severe neurological disorders, whose brains are already navigating a different and more difficult reality.

Lennox–Gastaut syndrome is one such severe condition, a form of epilepsy that begins in childhood and is characterized by frequent, drug-resistant seizures and significant cognitive impairment. Because this syndrome involves structural or genetic damage to the brain, doctors have long wondered if the same hormonal treatments used for typical children would work safely and effectively in this vulnerable group. A team of researchers at Yonsei University College of Medicine in South Korea set out to answer this question by looking back at the medical records of forty children who had both Lennox–Gastaut syndrome and central precocious puberty. Their goal was to see if the standard hormone-blocking treatment could successfully delay puberty and improve growth outcomes without causing harm to these children's neurological health.

The study focused on children who received gonadotropin-releasing hormone agonist treatment, a therapy that suppresses the body's natural production of sex hormones. The researchers tracked these patients over an average period of more than three years, starting when the children were roughly seven and a half years old. They monitored a wide range of factors, including how fast the children's bones were maturing compared to their actual age, their height and weight, and the levels of hormones in their blood. The results showed that the treatment worked exactly as intended for this difficult-to-treat group. The medication successfully suppressed the hormonal signals that drive puberty, keeping the children's sex hormone levels low throughout the treatment period. Crucially, the treatment also slowed down the rapid aging of their skeletons. At the start of the study, the children's bone age was significantly ahead of their actual age, but by the time treatment ended, this gap had narrowed considerably, bringing their skeletal development much closer to their chronological age.

While the treatment successfully managed the hormonal and skeletal aspects of the condition, the researchers observed that the children's growth patterns were influenced heavily by their underlying neurological struggles. The children did not gain as much height as typically developing children might have during the treatment, and their predicted adult height increased only slightly. However, the researchers noted that this modest gain was likely not a failure of the medication, but rather a reflection of the severe physical challenges these children face, such as limited mobility and nutritional difficulties, which are common in Lennox–Gastaut syndrome. When the treatment stopped, the children's bodies eventually resumed their natural development, with girls reaching their first menstrual period at an average age of nearly thirteen, a timing that aligns with what is seen in other groups of children treated for early puberty.

Safety was a primary concern, given that these children were already taking multiple medications to control their seizures. The researchers found no evidence that the puberty treatment made the seizures worse or required an increase in the number of seizure medications. In fact, the number of drugs the children took remained stable for most of the group. One child did stop the treatment early because their seizures seemed to increase, but the researchers could not prove that the puberty medication was the cause. The study also uncovered an interesting detail about the different causes of Lennox–Gastaut syndrome. Children whose condition was caused by a lack of oxygen to the brain at birth showed the most significant bone age advancement at the start of the study and experienced the largest improvement in their predicted adult height after treatment. This suggests that the specific cause of a child's neurological condition might influence how their body responds to puberty treatment, though the researchers emphasized that this finding needs to be confirmed in larger groups of patients.

Ultimately, this study provides a reassuring picture for families and doctors managing these complex cases. It demonstrates that the standard treatment for early puberty is effective and safe for children with Lennox–Gastaut syndrome, successfully delaying sexual maturation and slowing bone aging without disrupting their seizure management. The findings suggest that while the ultimate height these children achieve may be limited by the severity of their neurological condition, the treatment still offers a valuable window of time to manage their development. The researchers conclude that caring for these children requires a coordinated effort between neurologists and endocrinologists, ensuring that the management of puberty is tailored to the unique physical and functional needs of each child.